endocrinology
Medicines

Amputation risks re-assessed for SGLT2i

New analysis of pooled data has provided more reassurance that the SGLT2 inhibitor canagliflozin is not associated with a higher risk of limb amputations, Australian researchers say. The concern about amputation risk was raised years ago in CANVAS trial findings – and reported here in the limbic – but has not been reproduced in subsequent ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic